Ayala Pharmaceuticals, Inc.Ayala Pharmaceuticals, Inc.Ayala Pharmaceuticals, Inc.

Ayala Pharmaceuticals, Inc.

No trades
See on Supercharts

ADXS fundamentals

Key facts

Market capitalization
Founded
CEO
Website
About

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers. Its lead candidates are the oral gamma secretase inhibitor, AL102, for desmoid tumors, and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. The company was founded on June 5, 1987 and is headquartered in Monmouth Junction, NJ.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends
ADXS has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company